Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.

NCT Number	NCT07112170
Lead Sponsor	University Health Network, Toronto
Conditions	Metastatic Melanoma, OligoProgressive Metastatic Disease
Enrollment	52 participants
Start Date	2025-07-24
Primary Completion	2027-07-24 (estimated)
Study Completion	2028-07-24 (estimated)
Updated on ClinicalTrials.gov	2026-03-05